 |
Doug Macron is the editor of GenomeWeb's Gene Silencing News. He covers research and therapeutic applications of RNAi, miRNA, and other gene-silencing technologies. E-mail Doug Macron or follow his GenomeWeb Twitter account at @Genesilencing. |
Mirna Closes $34.5M Series C Round as microRNA Drugs Gain Investor Interest
October 25, 2012
Mirna Closes $34.5M Series C Round as microRNA Drugs Gain Investor Interest
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- In 2012, Top microRNA Drug Developers Pull in Nearly $150M in Funding
December 20, 2012 / Gene Silencing News - With Three Years of Cash in the Bank, Regulus Aims for Two INDs by 2014
November 29, 2012 / Gene Silencing News - As Evidence Grows for Role of microRNAs in Disease, Drugmakers Focus on Select Targets
December 16, 2010 / Gene Silencing News - Oligo Drugs Advance in the Clinic in 2012 as Delivery Hurdles are Addressed
January 3, 2013 / Gene Silencing News - Regulus Grosses a Total of $80.9M from Recent Transactions
November 8, 2012 / Gene Silencing News